Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance
- PMID: 7503771
- DOI: 10.1016/0006-2952(95)02069-1
Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance
Abstract
The intracellular pharmacokinetics and cytotoxicity of idarubicin (IDA), daunorubicin (DNR), and their corresponding C-13 alcohol metabolites, idarubicinol (IDAol) and daunorubicinol (DNRol), were studied in drug-sensitive HL-60/W human leukemia cells, and in two multidrug-resistant (MDR) sublines, HL-60/Vinc (overexpress P-glycoprotein, Pgp) and HL-60/Adr (overexpress multidrug resistance-associated protein, MRP). Intracellular drug accumulation (1 micrograms/mL) and retention were measured by flow cytometry. Mean intracellular steady-state concentration (Css, fluorescence units/cell) and area under the intracellular drug concentration x time curve (AUC, Fl.U/cell.min) were calculated. Relative to the values for the respective drugs in HL-60/W cells, the Css and AUC of IDA were much higher than those of DNR in the MDR cell lines, with Css and AUC of IDAol intermediate between IDA and DNR. In the MDR cell lines, the MDR modulator cyclosporine A (CsA), in concentrations of 0.3 to 30 mumol/L, caused minimal effects on 3-hr IDA accumulation, intermediate enhancement of IDAol accumulation, and greatest enhancement of DNR accumulation. The MDR cell lines were much less resistant to IDA (3- to 16-fold) than to DNR (65- to 117-fold). This difference was not the result of IDA being more potent than DNR, since the sensitivity of HL-60/W cells to IDA differed from their sensitivity to DNR by < 2-fold. The cellular pharmacokinetics and cytotoxicity of IDA in MDR human breast carcinoma cells MCF-7/AdrVp, which overexpress the putative MDR transporter P-95, were far superior to those of DNR, and were comparable to these parameters for IDA in parental MCF-7/W cells. These studies demonstrate that the cellular pharmacology and cytotoxicity of IDA in MDR cell lines that overexpress MRP, Pgp, or P-95 are more advantageous than those of DNR, suggesting that IDA is less susceptible to the transport-mediated MDR mechanism manifested. IDA is not completely invulnerable to MDR, however, since the MDR sublines studied did display a demonstrable level of resistance to IDA, compared with their drug-sensitive counterparts. IDAol, the major plasma metabolite of IDA, demonstrated behavior intermediate between the MDR-susceptible drug DNR and its parent compound, suggesting that its cytotoxic action is subject to transport-mediated cellular defenses.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
-
Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines.Leuk Res. 1999 Jun;23(6):539-48. doi: 10.1016/s0145-2126(99)00041-7. Leuk Res. 1999. PMID: 10374847
-
In vitro effect of multidrug resistance modifiers on idarubicinol efflux in blasts of acute myeloid leukemia.J Cancer Res Clin Oncol. 2000 Feb;126(2):111-6. doi: 10.1007/s004320050019. J Cancer Res Clin Oncol. 2000. PMID: 10664252 Free PMC article.
-
Idarubicin and idarubicinol are less affected by topoisomerase II-related multidrug resistance than is daunorubicin.Leuk Res. 1998 Jul;22(7):625-9. doi: 10.1016/s0145-2126(98)00060-5. Leuk Res. 1998. PMID: 9680113
-
Idarubicin: a brief overview on pharmacology and clinical use.Int J Clin Pharmacol Ther. 1997 Feb;35(2):80-3. Int J Clin Pharmacol Ther. 1997. PMID: 9147715 Review.
-
Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.Cancer Chemother Pharmacol. 1997;40 Suppl:S13-9. doi: 10.1007/s002800051055. Cancer Chemother Pharmacol. 1997. PMID: 9272128 Review.
Cited by
-
Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line.Br J Cancer. 1999 Feb;79(5-6):831-7. doi: 10.1038/sj.bjc.6690133. Br J Cancer. 1999. PMID: 10070877 Free PMC article.
-
Equipotent doses of daunorubicin and idarubicin for AML: a meta-analysis of clinical trials versus in vitro estimation.Cancer Chemother Pharmacol. 2019 Jun;83(6):1105-1112. doi: 10.1007/s00280-019-03825-2. Epub 2019 Apr 9. Cancer Chemother Pharmacol. 2019. PMID: 30968179 Free PMC article. Review.
-
Oral idarubicin. A review of its pharmacological properties and clinical efficacy in the treatment of haematological malignancies and advanced breast cancer.Drugs Aging. 1997 Jul;11(1):61-86. doi: 10.2165/00002512-199711010-00006. Drugs Aging. 1997. PMID: 9237041 Review.
-
Transport mechanisms of idarubicin, an anthracycline derivative, in human leukemia HL60 cells and mononuclear cells, and comparison with those of its analogs.Jpn J Cancer Res. 1997 Aug;88(8):750-9. doi: 10.1111/j.1349-7006.1997.tb00447.x. Jpn J Cancer Res. 1997. PMID: 9330607 Free PMC article.
-
Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720.Leukemia. 2011 May;25(5):800-7. doi: 10.1038/leu.2011.9. Epub 2011 Feb 15. Leukemia. 2011. PMID: 21321569 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous